Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates

Bae, Sung; Kim, Beom-Jun; Lim, Kyeong; Lee, Seung; Kim, Hong; Kim, Ghi; Koh, Jung-Min
September 2012
Journal of Bone & Mineral Metabolism;Sep2012, Vol. 30 Issue 5, p588
Academic Journal
We investigated rates of insufficient and over-responsiveness to orally administered bisphosphonates in postmenopausal women, and tested the efficacy of intravenous ibandronate in patients with insufficient response to orally administered bisphosphonates. Postmenopausal women were treated with either alendronate (70 mg/week; n = 88) or risedronate (35 mg/week; n = 84) for 1 year, and their response to orally administered bisphosphonates was assessed using serum C-telopeptide (CTX) levels. Insufficient responders were changed to once-quarterly intravenous ibandronate 3 mg injection ( n = 13) or maintained on orally administered bisphosphonates ( n = 19), according to patients' preference, for an additional 1 year. There was no significant difference in baseline characteristics between two orally administered bisphosphonate groups except the bone mineral density values at the lumbar spine. Insufficient rate was higher in the risedronate group (19.0 %) than in the alendronate group (8.0 %), using the premenopausal serum CTX median as a cut-off ( P = 0.043). The over-response rate among the alendronate group (59.1 %) was significantly higher than that in the risedronate group (38.1 %), based on a serum CTX cut-off value of 0.100 ng/ml ( P = 0.006). Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0.191 ± 0.110 ng/mL; P < 0.001) and 3 months after the fourth dosing (0.274 ± 0.159 ng/mL; P = 0.004) among insufficient responders, compared with post-oral/pre-intravenous levels (0.450 ± 0.134 ng/mL). Rates of insufficient and over-responsiveness to orally administered bisphosphonates were considerable, and a change to intravenous bisphosphonates may be considered in patients showing an insufficient response to orally administered bisphosphonates.


Related Articles

  • Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort). Kanterewicz, Eduardo; Peris, Pilar; Puigoriol, Emma; Yáñez, Aina; Rosique, Pau; Rio, Luis // Journal of Bone & Mineral Metabolism;Mar2013, Vol. 31 Issue 2, p231 

    This cross-sectional study evaluated the distribution of serum cross-linked C-telopeptides of collagen type I ( βCTXs) in postmenopausal women, the characteristics of bone remodeling, and the factors influencing this bone marker, especially the use of anti-osteoporotic drugs. Women ( n =...

  • Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAXâ„¢. Adler, R. A.; Hastings, F. W.; Petkov, V. I. // Osteoporosis International;Apr2010, Vol. 21 Issue 4, p647 

    Men treated by androgen deprivation therapy (ADT) for localized prostate cancer are at risk for fracture, but it is not known which men require pharmacologic treatment. We found that 33% of men on ADT had osteoporosis of spine, hip, or forearm by dual-energy X-ray absorptiometry (DXA), thus...

  • Hypovitaminosis D and prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women.  // BMC Women's Health;2012, Vol. 12 Issue 1, p11 

    The article presents a study which looks at the association of hypovitaminosis D with prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women. It notes that the study aims to determine the serum vitamin D status and to measure the association of vitamin D with bone mineral...

  • Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. Lateef, M.; Baig, M.; Azhar, A. // Osteoporosis International;May2010, Vol. 21 Issue 5, p751 

    A negative correlation of serum C-terminal telopeptide of type I collagen (telopeptide-C) was observed with bone mass density (BMD) in postmenopausal control ( r = −0.70, p < 0.05) and osteoporotic females ( r = −0.46, p < 0.05) indicating increased bone resorption in these subjects....

  • A postmenopausal osteoporotic woman losing bone mineral density despite bisphosphonates. Mei, Lai Pauline Siew; Thiagarajan, Nagammai; Vethakkan, Shireene Ratna // Malaysian Family Physician;2013, Vol. 8 Issue 2, p47 

    Bisphosphonates are pyrophosphate analogues, with a strong affinity for bones. They inhibit bone resorption and are currently the first choice of treatment for osteoporosis. Bisphosphonates should be taken in a specific manner and for at least one year to be effective in the maintenance and...

  • Postmenopozal Kadınlarda Risedronat ve Stronsiyum Ranelat’ın Kemik Mineral YoÄŸunluÄŸu Ãœzerine Etkisinin KarşılaÅŸtırılması. Yılmaz, Figen; Doğu, Beril; Şirzai, Hülya; Kuran, Banu // Turkish Journal of Osteoporosis / Turk Osteoporoz Dergisi;Aug2012, Vol. 18 Issue 2, p58 

    Aim: The purpose of our study is to compare the changes in bone mineral density (BMD) in postmenopausal women who had uninterrupted risedronate sodium and strontium ranelate treatment for 3 years. Material and Methods: Eighty-five postmenopausal women with primer osteoporosis who had...

  • Randomized Trial of Alendronate Plus Vitamin D Versus Standard Care in Osteoporotic Postmenopausal Women with Vitamin D Insufficiency. Ralston, Stuart; Binkley, Neil; Boonen, Steven; Kiel, Douglas; Reginster, Jean-Yves; Roux, Christian; Chen, Liang; Rosenberg, Elizabeth; Santora, Arthur // Calcified Tissue International;Jun2011, Vol. 88 Issue 6, p485 

    Vitamin D insufficiency is common in patients with osteoporosis. We conducted a randomized trial comparing alendronate 70 mg combined with vitamin D 5,600 IU in a single tablet (ALN/D5600, n = 257) with standard care chosen by the patients' personal physicians ( n = 258) in patients with...

  • Raloksifen ve Risedronatın Serum Biyokimyasal Belirteçler Ãœzerine Olan Etkilerinin DeÄŸerlendirilmesi. Yeter, Abdurrahman; Kavuncu, Vural; Evcik, Fatma Deniz; Demirdal, Ümit Seçil; Subaşı, Volkan; Çakır, Tuncay // Turkish Journal of Osteoporosis / Turk Osteoporoz Dergisi;Dec2014, Vol. 20 Issue 3, p110 

    Objective: Osteoporosis a progressive bone disease that is characterized by a decrease in bone mass which can lead to an increased risk of fracture. Osteoporosis is still a global public health problem. In recent years, many new osteoporosis drugs have become available but none of them is...

  • Premenopausal osteoporosis. Cheng, Marilyn Lee; Gupta, Vishal // Indian Journal of Endocrinology & Metabolism;Mar/Apr2013, Vol. 17 Issue 2, p240 

    Osteoporosis has traditionally been considered a disorder of postmenopausal women, but low bone mass and accelerated bone loss can also occur early in life causing premenopausal osteoporosis. There are a few risk factors that increase a woman's risk of premenopausal osteoporosis, including...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics